Treatment of Richter's Transformation with Novel Therapies.

IF 2.7 3区医学 Q2 HEMATOLOGY Current Hematologic Malignancy Reports Pub Date : 2024-04-01 Epub Date: 2024-01-09 DOI:10.1007/s11899-023-00721-8

Amneet Bajwa, Alma Habib, Adam S Kittai

{"title":"Treatment of Richter's Transformation with Novel Therapies.","authors":"Amneet Bajwa, Alma Habib, Adam S Kittai","doi":"10.1007/s11899-023-00721-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter's transformation (RT).Recent findings: Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials. Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-023-00721-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter's transformation (RT).

Recent findings: Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials. Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用新疗法治疗里希特氏变异。

综述的目的：本综述介绍了最近发表的临床试验数据和正在进行的有关治疗里氏变异（RT）的研究：最近，人们研究了多种治疗RT的方法，包括：传统的化疗免疫疗法与BTKi和BCL2i等靶向药物相结合；免疫疗法与靶向药物相结合；非共价BTKis；双特异性T细胞诱导剂；以及CART疗法。此外，目前正在进行各种新型靶向药物治疗 RT 的 1 期和 2 期临床试验研究。用化学免疫疗法治疗RT的标准疗法在实现持久缓解方面疗效有限。在此，我们回顾了在 RT 中使用联合疗法和靶向药物的最新数据。虽然在优化 RT 治疗的研究中取得了一些进展，但仍需进一步研究，以评估近期发表的试验的长期结果，并测试即将上市的新型药物的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊最新文献

Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas. JAK Inhibitors for Myelofibrosis: Strengths and Limitations. Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals. Prognostic and Predictive Models in Myelofibrosis. Systemic Mastocytosis: State of the Art.